Raised Amylase as a Potential Marker of Vascular Dysfunction and Inflammation in Fabry Disease
JIMD Reports · 2026-11 · 67 (6)
DOI: 10.1002/jmd2.70122 ↗Kurz gefasst
Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 09.11.2026. Verfasst von Simona D'Amore und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lysosomal Storage Disorders Unit Royal Free Hospital NHS Foundation Trust London UK. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fabry disease (FD) is a X‐linked disorder caused by deficiency of alpha‐galactosidase A (AGAL), leading to progressive accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso‐Gb3). While renal, cardiac and cerebrovascular complications are well described, pancreatic involvement remains poorly characterised. We retrospectively evaluated the clinical and biochemical features of FD patients with elevated serum amylase levels and explored associations with disease severity, treatment status, inflammation and vascular dysfunction. Sixty‐two patients (35 males, 27 females; median age 53.9 years [IQR 42.1–64.5]) showed hyperamylasaemia (> 100 U/L). None had known pancreatic disease or significant alcohol intake. Median amylase levels were 114.5 U/L (IQR 104–137). Seven patients were obese (body mass index ≥ 30 kg/m 2 ). No significant differences in amylase levels were observed according to sex, genotype, treatment status or renal/cerebrovascular involvement. However, patients with cardiac involvement had higher amylase levels than those without cardiac manifestations (median 128 [IQR 104–149] vs. 113 U/L [IQR 104.3–125]; p = 0.039). Amylase levels were not associated with AGAL activity, lyso‐Gb3 concentrations, renal function, liver function, d ‐dimer, lactate dehydrogenase or lipid profile. Significant correlations were observed with age ( r = 0.292; p = 0.021), body mass index ( r = −0.382; p = 0.003) and lipoprotein(a) levels ( r = 0.413; p = 0.004). Notably, elevated amylase occurred in the absence of clinically evident pancreatic disease, significant alcohol consumption or liver dysfunction. These findings suggest that hyperamylasaemia may represent an underrecognised biochemical feature of FD, potentially reflecting vascular and inflammatory mechanisms rather than overt pancreatic disease. Further studies are needed to clarify the pathophysiological significance of hyperamylasaemia in FD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lysosomal Storage Disorders Unit Royal Free Hospital NHS Foundation Trust London UK.
- University College London London UK.
ORCID-Profile: Simona D'Amore, Uma Ramaswami
Zitieren
APA
D'Amore, S., Cabides, M., & Ramaswami, U. (2026). Raised Amylase as a Potential Marker of Vascular Dysfunction and Inflammation in Fabry Disease. JIMD Reports, 67(6). https://doi.org/10.1002/jmd2.70122
Vancouver
D'Amore S, Cabides M, Ramaswami U. Raised Amylase as a Potential Marker of Vascular Dysfunction and Inflammation in Fabry Disease. JIMD Reports. 2026;67(6). doi:10.1002/jmd2.70122
BibTeX
@article{DAmore2026,
author = {D'Amore, Simona and Cabides, Ma and Ramaswami, Uma},
title = {Raised Amylase as a Potential Marker of Vascular Dysfunction and Inflammation in Fabry Disease},
journal = {JIMD Reports},
year = {2026},
volume = {67},
number = {6},
doi = {10.1002/jmd2.70122}
}
EUVIMED